综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果

doi:10.3969/j.issn.1006-7795.2020.04.005

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (4): 525-529.doi: 10.3969/j.issn.1006-7795.2020.04.005

综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果

豆竹丽¹, 阮祥燕^1,2, 鞠蕊¹, 王宾红¹, 秦爽¹, 许新¹, 杨瑜¹, 张露平¹

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院妇女健康部与妇女健康研究中心, 图宾根D-72076, 德国

收稿日期:2020-05-08 出版日期:2020-08-21 发布日期:2020-07-22
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
北京市医院管理中心"登峰"计划专项经费资助（DFL20181401），首都卫生发展科研专项（2020-2-2112）。

Clinical effect of letrozole on ovulation induction in infertile patients with polycystic ovary syndrome after comprehensive intervention

Dou Zhuli¹, Ruan Xiangyan^1,2, Ju Rui¹, Wang Binhong¹, Qin Shuang¹, Xu Xin¹, Yang Yu¹, Zhang Luping¹

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department for Women's Health, University Women's Hospital and Research Center for Women's Health, University of Tuebingen, Tuebingen D-72076, Germany

Received:2020-05-08 Online:2020-08-21 Published:2020-07-22
Supported by:
This study was supported by Beijing Hospitals Authority' Ascent Plan (DFL20181401),Capital's Funds for Health Improvement and Research (2020-2-2112).

摘要/Abstract

摘要： 目的探讨综合干预后采用来曲唑促排治疗多囊卵巢综合征不孕患者的临床效果。方法选取2019年3月至2019年9月就诊于首都医科大学附属北京妇产医院内分泌科的144例多囊卵巢综合征不孕患者作为研究对象，按照组间匹配的原则分为两组，观察组96例患者在接受综合干预治疗3个月后采用来曲唑治疗，对照组48例患者直接采用来曲唑治疗。观察综合干预组患者治疗前后激素浓度变化，包括黄体生成素（luteinizing hormone，LH）、卵泡刺激素（follicle stimulating hormone，FSH）、LH/FSH、总睾酮（total testosterone，TT）、游离睾酮（free testosterone，FT）、抗苗勒管激素（anti-Müllerian hormone，AMH）及腰围，比较两组患者的排卵率。结果两组患者治疗前不孕年限、身高、体质量、体质量指数（body mass index，BMI）、腰围、臀围、LH、FSH、AMH浓度比较差异均无统计学意义（P>0.05）；观察组患者综合干预后LH、FSH、LH/FSH、TT、FT、AMH浓度较治疗前显著降低（P<0.05），腰围较治疗前减低，但差异无统计学意义（P>0.05）；与对照组相比，观察组的排卵率明显升高，差异有统计学意义（P<0.05）。分层分析显示促排卵前BMI<24 kg/m²的患者中，观察组的排卵率高于对照组（P<0.05）；而BMI ≥ 24 kg/m²的患者中，两组的排卵率差异无统计学意义（P>0.05）。结论综合干预后采用来曲唑治疗多囊卵巢综合征不孕患者的临床效果显著，能够改善患者的激素浓度，提高排卵率，尤其是体质量指数控制在正常或偏低的患者效果更佳。

关键词: 多囊卵巢综合征, 不孕, 综合干预, 来曲唑, 促排卵

Abstract: Objective To investigate the clinical effect of letrozole in the treatment of infertile patients with polycystic ovary syndrome (PCOS) after comprehensive intervention. Methods A total of 144 infertile patients with PCOS who visited the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, from March to September 2019 were divided into two groups according to the principle of matching between groups. 96 patients in the observation group were treated with letrozole after 3 months of comprehensive intervention, while 48 patients in the control group were treated with letrozole alone. The changes of hormone levels before and after treatment were observed in the comprehensive intervention group, including luteinizing hormone (LH), follicle stimulating hormone (FSH), LH/FSH, total testosterone (TT), free testosterone (FT), anti-Müllerian hormone (AMH), and waist circumference. The ovulation rate was compared with each other between the two groups. Results There was no significant difference in infertility years, height, body weight, body mass index (BMI), waist circumference, hip circumference, LH, FSH and AMH between the two groups before treatment (P>0.05). After comprehensive intervention, the levels of LH, FSH, LH/FSH, TT, FT and AMH in the observation group were significantly lower than those before treatment (P<0.05), except that the waist circumference was lower than that before, but without statistically significant difference (P>0.05). Compared with the control group, the ovulation rate in the observation group was significantly increased, with statistically significant difference (P<0.05). Stratified analysis showed that the ovulation rate in the observation group was higher than that in the control group (P<0.05) in the patients with BMI<24 kg/m² before ovulation induction. However, in patients with BMI ≥ 24 kg/m², there was no significant difference between the two groups (P>0.05). Conclusion The clinical effect of letrozole in the treatment of infertility patients with PCOS after comprehensive intervention is significant, which can improve the both hormone level of patients and the ovulation rate, especially in patients with normal or low BMI.

Key words: polycystic ovary syndrome, infertility, comprehensive intervention, letrozole, ovulation induction

中图分类号:

R711.75

豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.

Dou Zhuli, Ruan Xiangyan, Ju Rui, Wang Binhong, Qin Shuang, Xu Xin, Yang Yu, Zhang Luping. Clinical effect of letrozole on ovulation induction in infertile patients with polycystic ovary syndrome after comprehensive intervention[J]. Journal of Capital Medical University, 2020, 41(4): 525-529.

参考文献 22

[1]	Alves E D, Bonfá A L O, Pigatto G R, et al. Photobiomodulation can improve ovarian activity in polycystic ovary syndrome-induced rats[J].J Photochem Photobiol B, 2019, 194:6-13.
[2]	Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome[J]. Fertil Steril, 2016,106(1):6-15.
[3]	Tannus S, Burke Y Z, Kol S. Treatment strategies for the infertile polycystic ovary syndrome patient[J]. Womens Health,2015,11(6):901-912.
[4]	中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志,2018,53(1):2-6.
[5]	Dumesic D A,Oberfield S E,Stener-Victorin E,et a1.Scientific statement on the diagnostic criteria,epidemiology,pathophysiology,and molecular genetics of polycystic ovary syndrome[J]. Endocr Rev,2015,36(5):487-525.
[6]	The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J].Hum Reprod,2004,19(1):41-47.
[7]	赵越,阮祥燕,李扬璐,等.来曲唑联合高纯度尿促性素治疗氯米芬耐药的多囊卵巢综合征不孕患者的临床研究[J].首都医科大学学报,2016,37(4):431-436.
[8]	Dumesic D A, Akopians A L, Madrigal V K, et al. Hyperandrogenism accompanies increased intra-Abdominal fat storage in normal weight polycystic ovary syndrome women[J]. J Clin Endocrinol Metab, 2016, 101(11):4178-4188.
[9]	柳顺玉,阮祥燕,刘玉兰.屈螺酮炔雌醇片预处理治疗多囊卵巢综合征不孕患者的临床效果[J].中国医学前沿杂志(电子版),2015,7(4):106-108.
[10]	闵敏,阮祥燕,赵越,等.奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J].首都医科大学学报,2019,40(4):572-577.
[11]	Dumont A, Robin G, Catteau-Jonard S, et al. Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome:a review[J].Reprod Biol Endocrinol,2015, 13:137-147.
[12]	Tian X, Ruan X, Mueck A O, et al. Anti-Müllerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China[J]. Gynecol Endocrinol, 2014, 30(2):126-129.
[13]	Tian X, Ruan X, Mueck A O, et al. Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China[J]. Gynecol Endocrinol, 2014, 30(11):836-839.
[14]	Jin J, Ruan X, Hua L, et al. Prevalence of diminished ovarian reserve in Chinese women with polycystic ovary syndrome and sensitive diagnostic parameters[J]. Gynecol Endocrinol, 2017,33(9):694-697.
[15]	罗棹文,周红.多囊卵巢综合征中抗苗勒管激素的相关研究进展[J]. 生殖医学杂志,2019,28(12):1521-1525.
[16]	李红然,张育婧,李春美,等. 多囊卵巢综合征不孕患者血清抗苗勒管激素水平与药物诱导排卵反应的关系[J]. 中华实用诊断与治疗杂志,2020,34(3):308-311.
[17]	Cela V,Obino M E R,Alberga Y,et al.Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes[J]. Gynecol Endocrinol,2018,34(6):518-523.
[18]	谢言信,赵雅男,林海燕,等.抗苗勒氏管激素在多囊卵巢综合征患者行人工授精预测价值的评估[J].中山大学学报(医学科学版),2019,40(1):90-97.
[19]	许远芳,黄元华.AMH在PCOS患者中评估卵巢储备及诊断价值[J].国际生殖健康/计划生育杂志,2019,38(3):230-235.
[20]	张素萍.来曲唑治疗不同体质量指数多囊卵巢综合征患者临床分析.济南:山东大学,2018.
[21]	山惠枝,沈晓月,蒋玥,等.体重指数对PCOS患者IVF/ICSI治疗的影响[J].生殖医学杂志,2019,28(6):629-635.
[22]	李予,马芸,李琳,等.体质指数对多囊卵巢综合征不孕患者体外受精治疗的影响[J].广东医学,2013,34(1):22-27.

综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果

Clinical effect of letrozole on ovulation induction in infertile patients with polycystic ovary syndrome after comprehensive intervention

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

[1]	金凤羽, 阮祥燕, 秦爽, 许新, 杨瑜, 谷牧青, 李妍秋, 杜娟, 程姣姣, 尹晓丹. 定坤丹治疗子宫内膜薄型不孕的临床效果[J]. 首都医科大学学报, 2022, 43(3): 364-368.
[2]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[3]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[4]	杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.
[5]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[6]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[7]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[8]	刘明明, 梁宇霆. 鞘管法子宫输卵管造影的临床价值[J]. 首都医科大学学报, 2020, 41(6): 982-985.
[9]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[10]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[11]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[12]	阮祥燕, 张露平, 代荫梅, 王虎生, 金凤羽, 谷牧青, 程姣姣, 鞠蕊, 闵敏, Thomas Roemer. 门诊微型宫腔镜检查在不孕症患者中的临床应用[J]. 首都医科大学学报, 2019, 40(4): 549-553.
[13]	谷牧青, 李扬璐, 程姣姣, 王虎生, 阮祥燕, 贾婵维. 达英-35对多囊卵巢综合征患者代谢与性激素的影响[J]. 首都医科大学学报, 2019, 40(4): 560-565.
[14]	闵敏, 阮祥燕, 赵越, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, 张露平, 王月姣, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(4): 572-577.
[15]	杜娟, 阮祥燕, Alfred O. Mueck. 口服避孕药对多囊卵巢综合征患者性功能的影响[J]. 首都医科大学学报, 2018, 39(4): 499-504.